Please assess the completion status of the following clinical trial:

Trial Title: Can Fatigability Neuromuscular Explain Chronic Fatigue in People With Multiple Sclerosis?

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~For Patients:~* Aged ≥ 18 and ≤ 70 years~* Men or women~* With multiple sclerosis since 2 and 25 years~* Affiliates or beneficiaries of social security scheme~* Signed consent~For Healthy volunteers:~* Aged ≥ 18 and ≤ 70 years~* Men or women~* Matched in accordance with age, sex and level of physical activity~Exclusion Criteria:~For Patients and Healthy volunteers:~* High heart rate resting~* Blood pressure \> 144/94 mmHg~* Recent adjustment of drug or drug can have an impact on fatigue or stimulant for fatigue~* Taking neuroactive substances that can alter corticospinal excitability~* Contraindication at application magnetic field~* Contraindication at Magnetic Resonance Imaging (MRI)~* Currently participating in a structured exercise program~* Pregnant~For Patients only:~* Spasticity or cerebellar ataxia~* Abnormal range of motion (toe and/or ankle)~* Musculoskeletal injuries that impedes pedaling~* Appearance of symptoms of multiple sclerosis in the 90 days preceding the study~For Healthy volunteers:~- Neurological diseases, cardiovascular, musculoskeletal

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- Patient with multiple sclerosis and lowly fatigued (Type: EXPERIMENTAL): Patient with multiple sclerosis and lowly fatigued will be included.~They will have:~Visit 1 (day 0) = Questionnaires, blood sample, cardiopulmonary evaluation, capacity of muscular oxygen extraction, sleep assessment Visit 2 (day 15) = Neuromuscular evaluation Visit 3 (day 30) = Metabolic fatigue
- Patient with multiple sclerosis and highly fatigued (Type: EXPERIMENTAL): Patient with multiple sclerosis and highly fatigued will be included. They will have:~Visit 1 (day 0) = Questionnaires, blood sample, cardiopulmonary evaluation, capacity of muscular oxygen extraction, sleep assessment Visit 2 (day 15) = Neuromuscular evaluation Visit 3 (day 30) = Metabolic fatigue
- Healthy subjects (Type: ACTIVE_COMPARATOR): Healthy subjects will be included. They will have:~Visit 1 (day 0) = Questionnaires, blood sample, cardiopulmonary evaluation, capacity of muscular oxygen extraction, sleep assessment Visit 2 (day 15) = Neuromuscular evaluation Visit 3 (day 30) = Metabolic fatigue

Based on this trial design, predict the completion outcome and termination type (if applicable).